Lytix Biopharma AS - Product Pipeline Review - 2014

  • July 2014
  • -
  • Global Markets Direct
  • -
  • 31 pages

Lytix Biopharma AS - Product Pipeline Review - 2014

Summary

Global Markets Direct’s, ‘Lytix Biopharma AS - Product Pipeline Review - 2014’, provides an overview of the Lytix Biopharma AS’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Lytix Biopharma AS’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Lytix Biopharma AS including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Lytix Biopharma AS’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Lytix Biopharma AS’s pipeline products

Reasons to buy

- Evaluate Lytix Biopharma AS’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Lytix Biopharma AS in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Lytix Biopharma AS’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Lytix Biopharma AS and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Lytix Biopharma AS
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Lytix Biopharma AS and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

Table of Contents
Table of Contents 2


Lytix Biopharma AS Snapshot 4
Lytix Biopharma AS Overview 4
Key Information 4
Key Facts 4
Lytix Biopharma AS - Research and Development Overview 5
Key Therapeutic Areas 5
Lytix Biopharma AS - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Combination Treatment Modalities 10
Lytix Biopharma AS - Pipeline Products Glance 11
Lytix Biopharma AS - Clinical Stage Pipeline Products 11
Phase II Products/Combination Treatment Modalities 11
Phase I Products/Combination Treatment Modalities 12
Lytix Biopharma AS - Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
Discovery Products/Combination Treatment Modalities 14
Lytix Biopharma AS - Drug Profiles 15
LTX-109 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
LTX-315 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
LTX-315 + tertomotide 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
Kinase Modulators 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
Lytix Biopharma AS - Pipeline Analysis 22
Lytix Biopharma AS - Pipeline Products by Target 22
Lytix Biopharma AS - Pipeline Products by Route of Administration 23
Lytix Biopharma AS - Pipeline Products by Molecule Type 24
Lytix Biopharma AS - Pipeline Products by Mechanism of Action 25
Lytix Biopharma AS - Recent Pipeline Updates 26
Lytix Biopharma AS - Dormant Projects 28
Lytix Biopharma AS - Locations And Subsidiaries 29
Head Office 29
Other Locations and Subsidiaries 29
Appendix 30
Methodology 30
Coverage 30
Secondary Research 30
Primary Research 30
Expert Panel Validation 30
Contact Us 31
Disclaimer 31



List of Tables

Lytix Biopharma AS, Key Information 4
Lytix Biopharma AS, Key Facts 4
Lytix Biopharma AS - Pipeline by Indication, 2014 7
Lytix Biopharma AS - Pipeline by Stage of Development, 2014 8
Lytix Biopharma AS - Monotherapy Products in Pipeline, 2014 9
Lytix Biopharma AS - Combination Treatment Modalities in Pipeline, 2014 10
Lytix Biopharma AS - Phase II, 2014 11
Lytix Biopharma AS - Phase I, 2014 12
Lytix Biopharma AS - Preclinical, 2014 13
Lytix Biopharma AS - Discovery, 2014 14
Lytix Biopharma AS - Pipeline by Target, 2014 22
Lytix Biopharma AS - Pipeline by Route of Administration, 2014 23
Lytix Biopharma AS - Pipeline by Molecule Type, 2014 24
Lytix Biopharma AS - Pipeline Products by Mechanism of Action, 2014 25
Lytix Biopharma AS - Recent Pipeline Updates, 2014 26
Lytix Biopharma AS - Dormant Developmental Projects,2014 28
Lytix Biopharma AS, Other Locations 29



List of Figures

Lytix Biopharma AS - Pipeline by Top 10 Indication, 2014 6
Lytix Biopharma AS - Pipeline by Stage of Development, 2014 8
Lytix Biopharma AS - Monotherapy Products in Pipeline, 2014 9
Lytix Biopharma AS - Pipeline by Top 10 Target, 2014 22
Lytix Biopharma AS - Pipeline by Top 10 Route of Administration, 2014 23
Lytix Biopharma AS - Pipeline by Top 10 Molecule Type, 2014 24
Lytix Biopharma AS - Pipeline Products by Top 10 Mechanism of Action, 2014 25

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Clare

+1 339 368 6001

Purchase Reports From Reputable Market Research Publishers

Neurofibromatoses Type II - Pipeline Review, H2 2014

Neurofibromatoses Type II - Pipeline Review, H2 2014

  • $ 2 000
  • Company report
  • July 2014
  • by Global Markets Direct

Neurofibromatoses Type II - Pipeline Review, H2 2014 Summary Global Markets Direct's, ‘Neurofibromatoses Type II - Pipeline Review, H2 2014', provides an overview of the Neurofibromatoses Type II's therapeutic ...

Hypertrophic Scars - Pipeline Review, H2 2014

Hypertrophic Scars - Pipeline Review, H2 2014

  • $ 2 000
  • Company report
  • July 2014
  • by Global Markets Direct

Hypertrophic Scars - Pipeline Review, H2 2014 Summary Global Markets Direct's, ‘Hypertrophic Scars - Pipeline Review, H2 2014', provides an overview of the Hypertrophic Scars's therapeutic pipeline. ...

Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H2 2014

Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H2 2014

  • $ 2 000
  • Company report
  • July 2014
  • by Global Markets Direct

Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H2 2014 Summary Global Markets Direct's, ‘Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H2 2014', provides an overview of the Uterine ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.